CN106170289B - 作为蛋白质激酶的调节剂的二芳基巨环 - Google Patents

作为蛋白质激酶的调节剂的二芳基巨环 Download PDF

Info

Publication number
CN106170289B
CN106170289B CN201580005705.5A CN201580005705A CN106170289B CN 106170289 B CN106170289 B CN 106170289B CN 201580005705 A CN201580005705 A CN 201580005705A CN 106170289 B CN106170289 B CN 106170289B
Authority
CN
China
Prior art keywords
fluoro
compound
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580005705.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106170289A (zh
Inventor
崔景荣
李一山
埃文·W·罗杰斯
翟大勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tepu Pharmaceutical
Turning Point Therapeutics Inc
Original Assignee
Tepu Pharmaceutical
TP Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tepu Pharmaceutical, TP Therapeutics Inc filed Critical Tepu Pharmaceutical
Priority to CN201910549748.XA priority Critical patent/CN110317214B/zh
Priority to CN201910549014.1A priority patent/CN110317213B/zh
Publication of CN106170289A publication Critical patent/CN106170289A/zh
Application granted granted Critical
Publication of CN106170289B publication Critical patent/CN106170289B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
CN201580005705.5A 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环 Active CN106170289B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910549748.XA CN110317214B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环
CN201910549014.1A CN110317213B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461931506P 2014-01-24 2014-01-24
US61/931,506 2014-01-24
US201462049326P 2014-09-11 2014-09-11
US62/049,326 2014-09-11
US201562106301P 2015-01-22 2015-01-22
US62/106,301 2015-01-22
PCT/US2015/012597 WO2015112806A2 (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910549748.XA Division CN110317214B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环
CN201910549014.1A Division CN110317213B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环

Publications (2)

Publication Number Publication Date
CN106170289A CN106170289A (zh) 2016-11-30
CN106170289B true CN106170289B (zh) 2019-07-23

Family

ID=53682127

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910549748.XA Active CN110317214B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环
CN201580005705.5A Active CN106170289B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环
CN201910549014.1A Active CN110317213B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910549748.XA Active CN110317214B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910549014.1A Active CN110317213B (zh) 2014-01-24 2015-01-23 作为蛋白质激酶的调节剂的二芳基巨环

Country Status (35)

Country Link
US (7) USRE50634E1 (enExample)
EP (6) EP3636650A1 (enExample)
JP (5) JP6490713B2 (enExample)
KR (1) KR102402179B1 (enExample)
CN (3) CN110317214B (enExample)
AP (1) AP2016009383A0 (enExample)
AU (2) AU2015209239B2 (enExample)
CA (1) CA2936079C (enExample)
CL (1) CL2016001876A1 (enExample)
CY (1) CY1121850T1 (enExample)
DK (3) DK3097107T3 (enExample)
EA (2) EA031863B1 (enExample)
ES (3) ES2735729T3 (enExample)
FI (2) FI3636649T3 (enExample)
FR (1) FR25C1013I1 (enExample)
HR (3) HRP20240503T1 (enExample)
HU (4) HUE060554T2 (enExample)
IL (2) IL246860B (enExample)
LT (4) LT3636649T (enExample)
MX (2) MX2016009588A (enExample)
MY (1) MY193524A (enExample)
NL (1) NL301322I2 (enExample)
NO (1) NO2025015I1 (enExample)
NZ (2) NZ761094A (enExample)
PE (1) PE20160931A1 (enExample)
PH (1) PH12016501463B1 (enExample)
PL (3) PL3097107T3 (enExample)
PT (3) PT3636649T (enExample)
RS (3) RS63829B1 (enExample)
SG (2) SG10202000191YA (enExample)
SI (3) SI3097107T1 (enExample)
SM (3) SMT202300008T1 (enExample)
UA (1) UA121206C2 (enExample)
WO (1) WO2015112806A2 (enExample)
ZA (2) ZA201604654B (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
PT3699181T (pt) 2014-11-16 2023-04-05 Array Biopharma Inc Forma cristalina de hidrogenossulfato de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
TN2017000502A1 (en) 2015-06-01 2019-04-12 Loxo Oncology Inc Methods of diagnosing and treating cancer
US10316044B2 (en) * 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
SMT202400213T1 (it) * 2015-07-06 2024-07-09 Turning Point Therapeutics Inc Polimorfo di diaril macrociclo
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
ES2818528T3 (es) * 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US11278521B2 (en) 2015-12-15 2022-03-22 University Of South Florida GAS5 binding compounds, formulations, and uses thereof
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
CN109414442B (zh) 2016-04-04 2024-03-29 洛克索肿瘤学股份有限公司 一种化合物的液体制剂
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3800189T3 (da) 2016-05-18 2023-07-31 Loxo Oncology Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
EP3490564A4 (en) * 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
EP3658148B1 (en) * 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3700576A1 (en) 2017-10-26 2020-09-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
US11098046B2 (en) 2017-11-10 2021-08-24 Angex Pharmaceutical, Inc. Macrocyclic compounds as TRK kinase inhibitors and uses thereof
US20210087206A1 (en) 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
MX2020006490A (es) 2017-12-19 2020-08-17 Turning Point Therapeutics Inc Compuestos macrociclicos para tratar enfermedades.
CN109456331B (zh) * 2017-12-22 2020-06-05 深圳市塔吉瑞生物医药有限公司 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111848622A (zh) * 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
WO2019149131A1 (zh) * 2018-01-30 2019-08-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN111971287B (zh) * 2018-03-28 2023-06-02 重庆复尚源创医药技术有限公司 作为trk激酶抑制剂的大环化合物
CA3095366A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
US11358973B2 (en) 2018-04-16 2022-06-14 Shenzhen Targetrx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
PL3786167T3 (pl) * 2018-04-25 2024-11-25 Primegene (Beijing) Co., Ltd. Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie
CN111918868B (zh) * 2018-05-04 2022-12-30 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CN110950889B (zh) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 一种多靶点激酶抑制剂及其制备方法和用途
CN112955453B (zh) * 2018-09-29 2022-04-19 山东绿叶制药有限公司 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
FI3870579T3 (fi) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
SG11202104609SA (en) * 2018-11-09 2021-06-29 Shandong Xuanzhu Pharma Co Ltd Macrocyclic tyrosine kinase inhibitor and uses thereof
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
WO2020106685A1 (en) * 2018-11-19 2020-05-28 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN111592541B (zh) * 2019-02-21 2021-09-10 山东轩竹医药科技有限公司 大环类激酶抑制剂及其用途
CN113811534B (zh) * 2019-03-11 2024-10-29 阿鲁米斯公司 Tyk2抑制剂和其用途
BR112021019070A2 (pt) * 2019-03-26 2022-02-15 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
CA3143043A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
CN112110938B (zh) * 2019-06-21 2021-11-09 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
US20220306653A1 (en) * 2019-06-21 2022-09-29 Janssen Pharmaceutica Nv Macrocyclic inhibitors of mcl-1
WO2021011586A1 (en) 2019-07-16 2021-01-21 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
KR20220134522A (ko) 2019-11-27 2022-10-05 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로시클릭 화합물을 수반하는 병용 요법
IL293206A (en) 2019-11-27 2022-07-01 Turning Point Therapeutics Inc Combination therapy involving diaryl macrocyclic compounds
US11634433B2 (en) 2019-12-03 2023-04-25 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
WO2021113492A1 (en) 2019-12-06 2021-06-10 Schrödinger, Inc. Cyclic compounds and methods of using same
CN113045587A (zh) * 2019-12-27 2021-06-29 成都倍特药业股份有限公司 一种大环结构化合物的晶型及其制备方法
BR112022012684A2 (pt) 2019-12-27 2023-03-07 Schroedinger Inc Compostos cíclicos e métodos de uso dos mesmos
CN113135938B (zh) * 2020-01-19 2022-06-14 山东轩竹医药科技有限公司 取代的大环类酪氨酸激酶抑制剂及其用途
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
PE20230609A1 (es) * 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
US20230183265A1 (en) * 2020-05-08 2023-06-15 Shandong Xuanzhu Pharma Co., Ltd. Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method therefor
WO2021244609A1 (zh) * 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CA3187834A1 (en) * 2020-07-10 2022-01-13 Blossomhill Therapeutics, Inc. Macrocycles and their use
US20230365584A1 (en) 2020-09-10 2023-11-16 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
US20240148732A1 (en) 2021-01-26 2024-05-09 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN113754657B (zh) * 2021-09-22 2023-01-17 广州白云山医药集团股份有限公司白云山制药总厂 大环类化合物的晶型及其制备方法和应用
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
CN116514813A (zh) * 2021-12-31 2023-08-01 轩竹生物科技股份有限公司 酪氨酸激酶抑制剂及其中间体的制备方法
JP2025503592A (ja) * 2022-01-05 2025-02-04 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状化合物およびキナーゼ阻害剤としての使用
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2025059027A1 (en) 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib
WO2025235733A1 (en) * 2024-05-09 2025-11-13 Blossomhill Therapeutics, Inc. Bis-bicycloheteroaryl macrocycles and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102143750A (zh) * 2008-09-08 2011-08-03 默克专利有限公司 用作蛋白激酶抑制剂的大环嘧啶
WO2012136859A1 (en) * 2011-04-07 2012-10-11 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ES2021105B3 (es) 1987-03-07 1991-10-16 Bayer Ag Procedimiento para la obtencion de 5-amino-4,6-dihalogeno piridinas.
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
EP1325008B1 (en) 2000-07-31 2005-10-05 F. Hoffmann-La Roche Ag Piperazine derivatives
AU2002227371B2 (en) 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7970766B1 (en) 2007-07-23 2011-06-28 Google Inc. Entity type assignment
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
JP5769199B2 (ja) 2008-10-31 2015-08-26 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20110029480A1 (en) * 2009-08-03 2011-02-03 IntelliCubes, Inc. Method of Compiling Multiple Data Sources into One Dataset
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
EP2509979B1 (en) 2009-12-07 2016-05-25 Boehringer Ingelheim International GmbH Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
KR20140053330A (ko) 2011-08-19 2014-05-07 머크 샤프 앤드 돔 코포레이션 마크로락탐의 제조를 위한 방법 및 중간체
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
JP6046728B2 (ja) 2011-09-30 2016-12-21 オンコデザイン エス．ア． 大環状ｆｌｔ３キナーゼ阻害剤
GB2495134B (en) 2011-09-30 2014-06-11 Tridonic Uk Ltd Power supply apparatus
BR112014009531A8 (pt) 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
PT2822953T (pt) 2012-03-06 2017-04-06 Pfizer Derivados macrocíclicos para o tratamento de doenças proliferativas
IN2014DN07384A (enExample) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
CA2866164C (en) 2012-03-09 2020-07-07 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
EP2645540A1 (de) 2012-03-28 2013-10-02 Siemens Aktiengesellschaft Glimmschutzwerkstoff für eine elektrische Maschine
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
HK1215250A1 (zh) 2013-01-30 2016-08-19 Bayer Pharma Aktiengesellschaft 氨基取代的异噻唑
EP2989082A1 (en) 2013-04-23 2016-03-02 LEK Pharmaceuticals d.d. Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
HRP20240937T1 (hr) 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
PE20181024A1 (es) 2015-05-05 2018-06-27 Bayer Pharma AG Derivados de ciclohexano sustituido con amido
ES2899219T3 (es) 2015-06-29 2022-03-10 Eitan Medical Ltd Sistema para determinar la movilidad de burbujas de aire dentro de un conducto de un dispositivo médico
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
SMT202400213T1 (it) 2015-07-06 2024-07-09 Turning Point Therapeutics Inc Polimorfo di diaril macrociclo
ES2818528T3 (es) 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
JP2020533269A (ja) 2016-12-14 2020-11-19 デベロップメント センター フォー バイオテクノロジー 抗体−薬物複合体およびその使用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102143750A (zh) * 2008-09-08 2011-08-03 默克专利有限公司 用作蛋白激酶抑制剂的大环嘧啶
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
WO2012136859A1 (en) * 2011-04-07 2012-10-11 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure

Also Published As

Publication number Publication date
ES2735729T3 (es) 2019-12-20
SI3572416T1 (sl) 2023-02-28
USRE50634E1 (en) 2025-10-14
LT3572416T (lt) 2022-12-27
US12404281B2 (en) 2025-09-02
EP4338739A2 (en) 2024-03-20
SMT202300008T1 (it) 2023-03-17
IL246860A0 (en) 2016-08-31
PT3097107T (pt) 2019-07-19
LTPA2025513I1 (enExample) 2025-04-25
SMT201900388T1 (it) 2019-09-09
EA031863B1 (ru) 2019-03-29
WO2015112806A2 (en) 2015-07-30
EP3636649A1 (en) 2020-04-15
HUS2500016I1 (hu) 2025-04-28
US10618912B2 (en) 2020-04-14
FIC20250015I1 (sv) 2025-03-20
EP3636649B1 (en) 2024-02-14
JP2019104748A (ja) 2019-06-27
IL268820B (en) 2021-10-31
RS59059B1 (sr) 2019-08-30
CN110317214B (zh) 2022-11-22
UA121206C2 (uk) 2020-04-27
RS65417B1 (sr) 2024-05-31
HRP20221518T1 (hr) 2023-02-17
EP3097107B1 (en) 2019-04-17
NZ761094A (en) 2023-02-24
US20200216465A1 (en) 2020-07-09
PL3572416T3 (pl) 2023-02-27
IL268820A (en) 2019-10-31
SMT202400175T1 (it) 2024-07-09
JP2022133462A (ja) 2022-09-13
CN110317214A (zh) 2019-10-11
CN110317213B (zh) 2022-10-18
DK3572416T3 (da) 2022-12-12
CA2936079A1 (en) 2015-07-30
ZA202004100B (en) 2023-12-20
EP4338739A3 (en) 2024-05-29
SG11201605929RA (en) 2016-08-30
SG10202000191YA (en) 2020-03-30
NZ722375A (en) 2022-11-25
KR20160111395A (ko) 2016-09-26
EP3636650A1 (en) 2020-04-15
AU2015209239A1 (en) 2016-07-14
HRP20191283T1 (hr) 2019-10-18
PT3572416T (pt) 2022-12-06
DK3636649T3 (da) 2024-05-21
EP3636648A1 (en) 2020-04-15
ZA201604654B (en) 2020-10-28
LT3097107T (lt) 2019-07-25
EA201691492A1 (ru) 2017-06-30
HUE045208T2 (hu) 2019-12-30
US10246466B2 (en) 2019-04-02
FR25C1013I1 (fr) 2025-06-20
IL246860B (en) 2019-09-26
AU2019279951A1 (en) 2020-01-16
HRP20240503T1 (hr) 2024-07-05
JP2017503867A (ja) 2017-02-02
NO2025015I1 (no) 2025-03-13
MY193524A (en) 2022-10-18
NL301322I2 (nl) 2025-05-27
PL3636649T3 (pl) 2024-05-06
DK3097107T3 (da) 2019-07-08
US20240140964A1 (en) 2024-05-02
US20190169207A1 (en) 2019-06-06
LT3636649T (lt) 2024-04-10
JP7356546B2 (ja) 2023-10-04
AU2015209239B2 (en) 2019-09-12
FI3636649T3 (fi) 2024-05-02
CA2936079C (en) 2022-07-19
HUE060554T2 (hu) 2023-03-28
US20170002023A1 (en) 2017-01-05
US20170334929A1 (en) 2017-11-23
MX2020001360A (es) 2020-03-20
AU2019279951B2 (en) 2021-08-12
CY1121850T1 (el) 2020-07-31
CN106170289A (zh) 2016-11-30
PH12016501463A1 (en) 2017-02-06
EP3572416A1 (en) 2019-11-27
PH12016501463B1 (en) 2017-02-06
US20220112213A1 (en) 2022-04-14
MX392904B (es) 2025-03-24
CL2016001876A1 (es) 2017-02-03
HUE066590T2 (hu) 2024-08-28
JP2021063121A (ja) 2021-04-22
ES2976459T3 (es) 2024-08-01
RS63829B1 (sr) 2023-01-31
MX2016009588A (es) 2017-05-15
SI3636649T1 (sl) 2024-07-31
EA201892241A1 (ru) 2019-02-28
PT3636649T (pt) 2024-04-09
ES2933350T3 (es) 2023-02-06
EP3097107A4 (en) 2017-08-09
CN110317213A (zh) 2019-10-11
SI3097107T1 (sl) 2019-08-30
US9714258B2 (en) 2017-07-25
EP3572416B1 (en) 2022-09-21
WO2015112806A3 (en) 2015-11-12
AP2016009383A0 (en) 2016-08-31
PL3097107T3 (pl) 2020-01-31
HK1231407A1 (zh) 2017-12-22
EP3097107A2 (en) 2016-11-30
KR102402179B1 (ko) 2022-05-25
JP2023179539A (ja) 2023-12-19
PE20160931A1 (es) 2016-09-21
JP6490713B2 (ja) 2019-03-27

Similar Documents

Publication Publication Date Title
CN106170289B (zh) 作为蛋白质激酶的调节剂的二芳基巨环
CN107735399A (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
TWI688567B (zh) 作為蛋白質激酶之調節劑的二芳基巨環
HK40015633B (en) Diaryl macrocycles as modulators of protein kinases
HK40015633A (en) Diaryl macrocycles as modulators of protein kinases
HK1231407B (zh) 作为蛋白质激酶的调节剂的二芳基巨环
HK40015634B (en) Diaryl macrocycles as modulators of protein kinases
HK40015634A (en) Diaryl macrocycles as modulators of protein kinases
HK40109104A (en) Diaryl macrocycles as modulators of protein kinases
HK40028407A (en) Diaryl macrocycles as modulators of protein kinases
EA041662B1 (ru) Способ ингибирования протеин- или тирозинкиназы в клетке с применением диарильного макроциклического соединения
BR112016017101B1 (pt) Compostos diaril macrociclos como moduladores das proteínas quinases e sua composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231407

Country of ref document: HK

CB02 Change of applicant information

Address after: American California

Applicant after: Tep Pharmaceutical Company

Address before: American California

Applicant before: TP biopharmaceutical company

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant